廣告

2018年8月18日 星期六

A ruling against a weedkiller could trigger an international regulatory battle併購風險難估:Bayer shares fall 10 percent after Monsanto's Roundup cancer trial

 Monsanto 公司固然在轉基因農業領先,可是,
Bayer之併購風險難估,尤其是美國的集體訴訟 (class action)。

A regulatory crackdown on glyphosate would not only hit sales of pesticides and weedkillers, but also the seeds that firms have developed to be used with them

Bayer shares plunged more than 10 percent after a California jury ordered the German company's newly acquired Monsanto subsidiary to pay $289 million for not warning of cancer risks posed by its main weed killer. https://reut.rs/2KNGwKc

沒有留言:

網誌存檔